Rapport Therapeutics, Inc. Common Stock Stock Analysis & AI Score
Rapport Therapeutics, Inc. Common Stock (RAPP) has an ST Score of 47.1 (C+), driven by its Financial Strength (A-) and held back by its Growth (F). Analysts rate it Buy with a $67.33 price target (+99.0% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Rapport Therapeutics, Inc. Common Stock (RAPP) has an ST Score of 47.1 (C+), driven by its Financial Strength (A-) and held back by its Growth (F). Analysts rate it Buy with a $67.33 price target (+99.0% upside).
- Strongest
- Financial StrengthA-
- Weakest
- GrowthF
All factor grades
- Financial StrengthA-
- ForecastA-
- ProfitabilityB
- MomentumC+
- SentimentC+
- ValuationC
- GrowthF
- Piotroski2/9
Contact
RAPP stock: frequently asked questions
What is RAPP's ST Score?
Rapport Therapeutics, Inc. Common Stock (RAPP) has an ST Score of 47.1 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RAPP a buy, hold, or sell?
Analysts rate RAPP a Buy, with a price target of $67.33 (+99.0% vs the current price). Our ST Score grades it C+ (47.1/100). The ST Score is a data-driven signal, not a recommendation.
What are RAPP's factor grades?
Valuation C, Profitability B, Financial Strength A-, Momentum C+, Growth F, Forecast A-, Sentiment C+.
What is RAPP's valuation grade?
Rapport Therapeutics, Inc. Common Stock (RAPP) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RAPP's growth grade?
Rapport Therapeutics, Inc. Common Stock (RAPP) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RAPP's profitability grade?
Rapport Therapeutics, Inc. Common Stock (RAPP) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RAPP's financial strength grade?
Rapport Therapeutics, Inc. Common Stock (RAPP) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for RAPP?
The average analyst price target for Rapport Therapeutics, Inc. Common Stock (RAPP) is $67.33 from 5 analysts, which is +99.0% versus the recent price of $33.83.
What is RAPP's Piotroski score?
Rapport Therapeutics, Inc. Common Stock (RAPP) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.